AU725817B2 - Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist - Google Patents

Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist Download PDF

Info

Publication number
AU725817B2
AU725817B2 AU42972/97A AU4297297A AU725817B2 AU 725817 B2 AU725817 B2 AU 725817B2 AU 42972/97 A AU42972/97 A AU 42972/97A AU 4297297 A AU4297297 A AU 4297297A AU 725817 B2 AU725817 B2 AU 725817B2
Authority
AU
Australia
Prior art keywords
disorder
disorders
antagonist
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU42972/97A
Other languages
English (en)
Other versions
AU4297297A (en
Inventor
Thomas Paul Blackburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU4297297A publication Critical patent/AU4297297A/en
Application granted granted Critical
Publication of AU725817B2 publication Critical patent/AU725817B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU42972/97A 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist Ceased AU725817B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9615767.2A GB9615767D0 (en) 1996-07-26 1996-07-26 Novel treatment
GB9615767 1996-07-26
PCT/EP1997/004159 WO1998004289A2 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist

Publications (2)

Publication Number Publication Date
AU4297297A AU4297297A (en) 1998-02-20
AU725817B2 true AU725817B2 (en) 2000-10-19

Family

ID=10797573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42972/97A Ceased AU725817B2 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist

Country Status (19)

Country Link
EP (1) EP0936924A2 (no)
JP (1) JP2000516924A (no)
KR (1) KR20000029564A (no)
CN (1) CN1230894A (no)
AR (1) AR008083A1 (no)
AU (1) AU725817B2 (no)
BR (1) BR9710568A (no)
CA (1) CA2261813A1 (no)
CO (1) CO5031292A1 (no)
CZ (1) CZ23799A3 (no)
GB (1) GB9615767D0 (no)
HU (1) HUP9903619A3 (no)
IL (1) IL128219A0 (no)
NO (1) NO990322L (no)
NZ (1) NZ333813A (no)
PL (1) PL331426A1 (no)
TR (1) TR199900140T2 (no)
WO (1) WO1998004289A2 (no)
ZA (1) ZA976593B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
CA2351718A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
WO2000030649A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
WO2000054764A2 (en) * 1999-03-18 2000-09-21 Children's Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
EP1223939A1 (en) * 1999-05-19 2002-07-24 AstraZeneca AB Method of treating weight gain
WO2005013969A1 (en) * 2003-07-15 2005-02-17 Janssen Pharmaceutica N.V. Antipsychotic agent with socializing properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500998D0 (sv) * 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics

Also Published As

Publication number Publication date
ZA976593B (en) 1999-01-25
HUP9903619A2 (hu) 2000-10-28
HUP9903619A3 (en) 2001-03-28
NO990322L (no) 1999-03-24
PL331426A1 (en) 1999-07-19
WO1998004289A3 (en) 1998-03-19
KR20000029564A (ko) 2000-05-25
EP0936924A2 (en) 1999-08-25
CN1230894A (zh) 1999-10-06
WO1998004289A2 (en) 1998-02-05
CZ23799A3 (cs) 1999-06-16
CA2261813A1 (en) 1998-02-05
IL128219A0 (en) 1999-11-30
NO990322D0 (no) 1999-01-25
BR9710568A (pt) 1999-08-17
NZ333813A (en) 2000-07-28
GB9615767D0 (en) 1996-09-04
AU4297297A (en) 1998-02-20
CO5031292A1 (es) 2001-04-27
TR199900140T2 (xx) 1999-03-22
JP2000516924A (ja) 2000-12-19
AR008083A1 (es) 1999-12-09

Similar Documents

Publication Publication Date Title
DE60218037T2 (de) Neue indolderivate mit affinität zum 5-ht6-rezeptor
US6025367A (en) Sulfonamide derivatives as 5HT7 receptor antagonists
US5760234A (en) Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands
DE60122767T2 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
JP2000512645A (ja) スルホンアミド誘導体およびｃｎｓ障害の治療におけるそれらの使用
PT689536E (pt) Derivados de naftaleno
JPH09501171A (ja) ５ｈｔ１ｄ受容体アンタゴニストとしてのアミド誘導体
JPH09502177A (ja) ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体
RU2198888C2 (ru) 3-замещенные производные 3,4,5,6,7,8-гексагидропиридо[4',3':4,5]-тиено[2,3-d]пиримидина
JP2005525332A (ja) ５−ｈｔ６受容体アフィニティーを有するスルホニル化合物
US6080758A (en) Benzenesulfonamide derivatives as bradykinin antagonists
EP0445781B1 (en) 3-Arylcarbonyl-1-aminoalkyl-1H-indole containing antiglaucoma compositions
WO1997008167A1 (en) 5ht2c and 5ht2b antagonists
JP5062939B2 (ja) セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
AU725817B2 (en) Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist
KR100924405B1 (ko) 뉴로키닌 수용체 길항제로서의 신규한ｎ-트리아졸일메틸-피페라진 유도체
EP0912556B1 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
US5175158A (en) Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
US4868190A (en) N-pyridinyl-9H-carbazol-9-amines
US6369060B1 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
WO1998052943A1 (en) Indoline derivatives as 5ht2c receptor antagonists
KR840002139B1 (ko) 벤조퀴놀리진의 제조방법
TW206230B (no)
EP0743946A1 (en) 5ht2b receptor antagonists condensed indoles
US6002005A (en) Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired